Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Oncology > 2026 Vol. 1 > No. 1 > 100008
Next Article Previous Article
COMMENTARY   Open Access     Cite

Targeting macrophages: A new frontier in cancer immunotherapy with CAR-NK cells

  • 1.

    Department of Emergency, the First Affiliated Hospital of Anhui Medical University, Hefei 230027, China

  • 2.

    Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China

  • 3.

    State Key Laboratory of Immune Response and Immunotherapy, University of Science and Technology of China, Hefei 230001, China

  • 4.

    Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu 233030, China

  • 5.

    Cell and Regenerative Medicine Research and Development Center, Zhongke Hefei Institute of Technology Innovation Engineering, Hefei 230027, China

More Information
  • Corresponding author: dywsn@ustc.edu.cn
  • Received Date:  March 01, 2026
    Accepted Date:  April 20, 2026
    Published Online:  April 23, 2026
The Innovation Oncology  1(1),  https://doi.org/10.59717/j.xinn-oncol.2026.100008  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Maalej K.M., Merhi M., Inchakalody V.P., et al. (2023). CAR-cell therapy in the era of solid tumor treatment: Current challenges and emerging therapeutic advances. Mol. Cancer 22:20. DOI:10.1186/s12943-023-01723-z

    View in Article CrossRef Google Scholar

    [2] Sun X., Park M.D., Merad M., et al. (2026). Macrophages: Targets for next-generation cancer immunotherapy. Cancer Cell 44:498−518. DOI:10.1016/j.ccell.2026.01.020

    View in Article CrossRef Google Scholar

    [3] Johnson M., Dudek A.Z., Sukari A., et al. (2022). ARRY-382 in Combination with pembrolizumab in patients with advanced solid tumors: Results from a phase 1b/2 study. Clin. Cancer Res. 28:2517−2526. DOI:10.1158/1078-0432.CCR-21-3009

    View in Article CrossRef Google Scholar

    [4] Jin J., Yan P., Wang D., et al. (2025). Targeting lactylation reinforces NK cell cytotoxicity within the tumor microenvironment. Nat. Immunol. 26:1099−1112. DOI:10.1038/s41590-025-02178-8

    View in Article CrossRef Google Scholar

    [5] Zhu X., Xue J., Jiang H., et al. (2024). CAR-NK cells for gastrointestinal cancer immunotherapy: From bench to bedside. Mol. Cancer 23:237. DOI:10.1186/s12943-024-02151-3

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Dai X. and Wang D. (2026). Targeting macrophages: A new frontier in cancer immunotherapy with CAR-NK cells. The Innovation Oncology 1:100008. https://doi.org/10.59717/j.xinn-oncol.2026.100008
    Dai X. and Wang D. (2026). Targeting macrophages: A new frontier in cancer immunotherapy with CAR-NK cells. The Innovation Oncology 1:100008. https://doi.org/10.59717/j.xinn-oncol.2026.100008

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(756) PDF downloads(318)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.